{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T14:36:43Z","timestamp":1769006203728,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University","award":["ZYJC18010"],"award-info":[{"award-number":["ZYJC18010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s12325-021-01926-0","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T03:11:37Z","timestamp":1634613097000},"page":"5662-5670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States"],"prefix":"10.1007","volume":"38","author":[{"given":"Weiting","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanting","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuji","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kexun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangliang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"1926_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"1926_CR2","unstructured":"Padala SA, Kallam A. Clear cell renal carcinoma. In: StatPearls. Treasure Island (FL): StatPearls Publishing; Aug 2, 2021."},{"key":"1926_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","volume":"23","author":"CJ Ricketts","year":"2018","unstructured":"Ricketts CJ, De Cubas AA, Fan H, et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23:313\u201326.","journal-title":"Cell Rep"},{"key":"1926_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11864-020-00814-z","volume":"22","author":"BR Christensen","year":"2021","unstructured":"Christensen BR, Hajja YM, Koshkin V, Barata PC. Update on first-line combination treatment approaches in metastatic clear-cell renal cell carcinoma. Curr Treat Options Oncol. 2021;22:15.","journal-title":"Curr Treat Options Oncol"},{"key":"1926_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/jcpt.13282","volume":"46","author":"JH Heo","year":"2021","unstructured":"Heo JH, Park C, Ghosh S, Park SK, Zivkovic M, Rascati KL. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma. J Clin Pharm Ther. 2021;46:35\u201349.","journal-title":"J Clin Pharm Ther"},{"key":"1926_CR6","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","volume":"25","author":"LQ Chow","year":"2007","unstructured":"Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25:884\u201396.","journal-title":"J Clin Oncol"},{"key":"1926_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115\u201324.","journal-title":"N Engl J Med"},{"key":"1926_CR8","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584\u201390.","journal-title":"J Clin Oncol"},{"key":"1926_CR9","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10:2298\u2013308.","journal-title":"Mol Cancer Ther"},{"key":"1926_CR10","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","volume":"35","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35:591\u20137.","journal-title":"J Clin Oncol"},{"key":"1926_CR11","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803\u201313.","journal-title":"N Engl J Med"},{"key":"1926_CR12","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384:829\u201341.","journal-title":"N Engl J Med"},{"key":"1926_CR13","unstructured":"US Food and Drug Administration. FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma. 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-plus-cabozantinib-advanced-renal-cell-carcinoma. Accessed 14 Feb 2021."},{"key":"1926_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40273-018-0746-y","volume":"37","author":"CR Chien","year":"2019","unstructured":"Chien CR, Geynisman DM, Kim B, Xu Y, Shih YT. Economic burden of renal cell carcinoma-part I: an updated review. Pharmacoeconomics. 2019;37:301\u201331.","journal-title":"Pharmacoeconomics"},{"key":"1926_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3111\/13696998.2014.985789","volume":"18","author":"A Perrin","year":"2015","unstructured":"Perrin A, Sherman S, Pal S, et al. Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US. J Med Econ. 2015;18:200\u20139.","journal-title":"J Med Econ"},{"key":"1926_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s40425-018-0440-9","volume":"6","author":"B Wu","year":"2018","unstructured":"Wu B, Zhang Q, Sun J. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma. J Immunother Cancer. 2018;6:124.","journal-title":"J Immunother Cancer"},{"key":"1926_CR17","unstructured":"IBM Corporation. RED BOOK Online\u00ae\/Micromedex [database online]. 2021. http:\/\/www.micromedexsolutions.com. Accessed 22 Feb 2021."},{"key":"1926_CR18","unstructured":"The U.S. Labor Department's Bureau of Labor Statistics. US Inflation Calculator. 2021. https:\/\/www.usinflationcalculator.com. Accessed 17 Mar 2021."},{"key":"1926_CR19","first-page":"2634","volume":"123","author":"X Wan","year":"2017","unstructured":"Wan X, Peng L, Ma J, Li Y. Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives. Cancer Am Cancer Soc. 2017;123:2634\u201341.","journal-title":"Cancer Am Cancer Soc"},{"issue":"4","key":"1926_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/jamaoncol.2018.7086","volume":"5","author":"X Wan","year":"2019","unstructured":"Wan X, Zhang Y, Tan C, Zeng X, Peng L. First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: A cost-effectiveness analysis. JAMA Oncol. 2019;5(4):491\u20136.","journal-title":"JAMA Oncol."},{"key":"1926_CR21","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.eururo.2017.07.041","volume":"73","author":"M Sarfaty","year":"2018","unstructured":"Sarfaty M, Leshno M, Gordon N, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. 2018;73:628\u201334.","journal-title":"Eur Urol"},{"key":"1926_CR22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371:796\u20137.","journal-title":"N Engl J Med"},{"key":"1926_CR23","first-page":"431402057","volume":"12","author":"Y Su","year":"2020","unstructured":"Su Y, Fu J, Du J, Wu B. First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis. Ther Adv Med Oncol. 2020;12:431402057.","journal-title":"Ther Adv Med Oncol"},{"key":"1926_CR24","doi-asserted-by":"publisher","first-page":"e215761","DOI":"10.1371\/journal.pone.0215761","volume":"14","author":"B Deniz","year":"2019","unstructured":"Deniz B, Ambavane A, Yang S, et al. Treatment sequences for advanced renal cell carcinoma: a health economic assessment. PLoS ONE. 2019;14:e215761.","journal-title":"PLoS ONE"},{"key":"1926_CR25","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.jval.2011.04.004","volume":"14","author":"B Goulart","year":"2011","unstructured":"Goulart B, Ramsey S. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health. 2011;14:836\u201345.","journal-title":"Value Health."},{"key":"1926_CR26","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","volume":"10","author":"LJ Garrison","year":"2007","unstructured":"Garrison LJ, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007;10:326\u201335.","journal-title":"Value Health"},{"key":"1926_CR27","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.eururo.2014.12.017","volume":"68","author":"AV Soerensen","year":"2015","unstructured":"Soerensen AV, Donskov F, Kjellberg J, et al. Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA Study 2. Eur Urol. 2015;68:516\u201322.","journal-title":"Eur Urol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01926-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01926-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01926-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T19:10:11Z","timestamp":1636225811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01926-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1926"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01926-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"assertion":[{"value":"12 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}